Kevin Schuyler - 29 May 2025 Form 4 Insider Report for ADIAL PHARMACEUTICALS, INC. (ADIL)

Reporting relationship
Director
Issuer ticker
ADIL
Reported as of
29 May 2025
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
02 Jun 2025, 16:01:32 UTC
Prior SEC filing
21 May 2025
Next SEC filing
19 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Kevin Schuyler

Key filing fact

Kevin Schuyler filed Form 4 for ADIAL PHARMACEUTICALS, INC. (ADIL) on 02 Jun 2025.

Key facts

  • This page summarizes Kevin Schuyler's Form 4 filing for ADIAL PHARMACEUTICALS, INC. (ADIL).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 02 Jun 2025, 16:01.

Change

  • Previous filing in this sequence was filed on 21 May 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001718094 Primary reporting owner

Schuyler Kevin

Relationship
Director
Address
4870 SADLER ROAD,, STE 300, GLEN ALLEN,
Signature
/s/ Kevin Schuyler
Signature date
02 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADIL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+28,000
Change %
Price
$0.000000
Shares after
28,000
Date
29 May 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
28,000
Exercise price
$0.6880
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .